Clinical trial · Interventional
Ga-68 FAPI PET Before Immunotherapy
Prognostic Significance of Ga-68 FAPI PET Before Immunotherapy in Pleural Mesothelioma
NCT06451536CI-TRIAL-00077861FAPBIunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
It is aimed to evaluate FAP expression and its success in predicting treatment response before immunotherapy used in the treatment of malignant mesothelioma with Ga68 FAPI PET/CT imaging, which allows in vivo evaluation of FAP expression, which is thought to be associated with immunosuppression and resistance to immunotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Mesotheliomas Pleural | Malignant Mesothelioma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ga-68 FAPI PET/CT | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Treatment arm
- description
- Patients underwent Ga68 FAPI PET before immunotherapy
- interventionNames
- Diagnostic Test: Ga-68 FAPI PET/CT
Primary outcomes (3)
- measure
- Prediction of immune therapy response with Ga-68 FAPI PET
- timeFrame
- 6. month after initiation of therapy
- description
- prediction of immunotherapy response with SUVmax measured with Ga-68 FAPI PET before immunotherapy
- measure
- Prediction of immune therapy response with Ga-68 FAPI PET
- timeFrame
- 6. month after initiation of therapy
- description
- prediction of immunotherapy response with total FAPI volume measured with Ga-68 FAPI PET before immunotherapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Having a histopathologically confirmed diagnosis of * Pleural Mesolthelioma * Patients scheduled for immunotherapy with anti-PDL-1 and/or anti-CTLA-4 antibodies as first or second line therapy * Patients who gave informed consent form to participate in the study Exclusion Criteria: * ECOG\>2 * Patients who did not provide informed consent form to participate in the study
References
Publications (0)
Data not yet available
No reference posted for this study.